Strongbridge Drug Patent Portfolio
Strongbridge owns 1 orange book drug protected by 8 US patents Given below is the list of Strongbridge's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11020393 | Methods of treating disease with levoketoconazole | 02 Mar, 2040 | Active |
US11278547 | Methods of treating disease with levoketoconazole | 02 Mar, 2040 | Active |
US11903940 | Methods of treating disease with levoketoconazole | 02 Mar, 2040 | Active |
US10098877 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions | 10 Jan, 2026 | Active |
US10517868 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions | 10 Jan, 2026 | Active |
US10835530 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions | 10 Jan, 2026 | Active |
US11478471 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions | 10 Jan, 2026 | Active |
US9918984 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions | 10 Jan, 2026 | Active |
Latest Legal Activities on Strongbridge's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Strongbridge.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 4th Yr, Small Entity | 06 May, 2024 | US10835530 |
transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US9918984 |
Recordation of Patent Grant Mailed
Critical
| 20 Feb, 2024 | US11903940 |
Patent eGrant Notification | 20 Feb, 2024 | US11903940 |
Patent Issue Date Used in PTA Calculation
Critical
| 20 Feb, 2024 | US11903940 |
Recordation of Patent eGrant | 20 Feb, 2024 | US11903940 |
Email Notification
Critical
| 20 Feb, 2024 | US11903940 |
Mail Patent eGrant Notification | 20 Feb, 2024 | US11903940 |
Email Notification
Critical
| 01 Feb, 2024 | US11903940 |
Issue Notification Mailed
Critical
| 31 Jan, 2024 | US11903940 |
Application Is Considered Ready for Issue
Critical
| 10 Jan, 2024 | US11903940 |
Dispatch to FDC | 10 Jan, 2024 | US11903940 |
Issue Fee Payment Verified
Critical
| 05 Jan, 2024 | US11903940 |
Issue Fee Payment Received
Critical
| 05 Jan, 2024 | US11903940 |
Electronic Review
Critical
| 12 Dec, 2023 | US11903940 |
Strongbridge's Family Patents
Strongbridge Drug List
Given below is the complete list of Strongbridge's drugs and the patents protecting them.
1. Recorlev
Recorlev is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11020393 | Methods of treating disease with levoketoconazole |
02 Mar, 2040
(15 years from now)
| Active |
US11278547 | Methods of treating disease with levoketoconazole |
02 Mar, 2040
(15 years from now)
| Active |
US11903940 | Methods of treating disease with levoketoconazole |
02 Mar, 2040
(15 years from now)
| Active |
US10098877 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
10 Jan, 2026
(1 year, 19 days from now)
| Active |
US10517868 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
10 Jan, 2026
(1 year, 19 days from now)
| Active |
US10835530 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
10 Jan, 2026
(1 year, 19 days from now)
| Active |
US11478471 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
10 Jan, 2026
(1 year, 19 days from now)
| Active |
US9918984 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
10 Jan, 2026
(1 year, 19 days from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Recorlev's drug page